Aktuellt
SENASTE
Redeye remains positive on the case as we see Heliospectra very well positioned to benefit from the long-term growth trends in the Aghort industry. Business has been impacted by the global pandemic and we now expect a general recovery in the market as conditions are improving. A stronger sales organization and improved offering, including the launch of biosensor systems in 2022, will in our view give excellent growth opportunities.
LÄS MER
